Beyond biology: Nanobiotix's physics-first approach to cancer

What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic.Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead asset is a radioenhancer made of hafnium oxide nanoparticles, designed to be injected directly into a tumor and amplify the destructive power of radiotherapy from within — without increasing damage to surrounding healthy tissue. It is currently in Phase 3 trials in head and neck cancer.But that's only half the story. The company's Nanoprimer platform is now emerging as a potential new engine for growth — with the promise of making an entirely new class of genetic medicines work better.02:47 Meet Laurent Lévy06:04 What physics offers that biology cannot 11:12 How JNJ-1900 (NBTXR3) works 15:14 The immune effect 18:16 Pipeline milestones ahead20:56 The Curadigm Nanoprimer platform 25:32 The oversubscribed €85 million raiseInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III ResultsGet to know 15 of the best biotech companies in ParisEight nanotechnology companies to watch out for